Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest

(MedPage Today) – New data suggests that donanemab (Kisunla) shows long-term benefits after a limited dosing period in a subgroup of people with early symptoms of Alzheimer’s disease. The first patients with Alzheimer’s disease to complete their course…